Latest Headlines

  1. PathAI Launches Industry-Backed AIM-HI UC Model On GCP-Compliant Platform To Standardize Histological Assessment In Ulcerative Colitis Trials 9/23/2025

    PathAI, the global leader in AI-powered pathology, today announced the integration of AIM-HI UC1, an advanced AI model for Ulcerative Colitis (UC) histology endpoint assessment, on to AISight Clinical Trials, PathAI’s GCP and GCLP-compliant platform.

  2. Quest Diagnostics To Improve Laboratory Testing Experience With Industry-First Epic Collaboration 9/23/2025

    Quest Diagnostics (NYSE: DGX) and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for healthcare providers and patients that engage Quest for laboratory testing in the United States.

  3. Myriad Genetics And SOPHiA GENETICS To Develop An Innovative Companion Diagnostic Offering In Liquid Biopsy 9/23/2025

    Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.

  4. PacBio Enters High-Throughput Carrier Screening Market With Standalone HiFi Sequencing Assay For Challenging Genes 9/22/2025

    PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the high-throughput carrier screening market with a significantly expanded and enhanced suite of PureTarget products.

  5. SOPHiA GENETICS Expands Collaboration With AstraZeneca To Enhance Detection Of Breast And Prostate Cancer 9/22/2025

    SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston.

  6. LabWare Launches Clinical Health Solution 5.06 9/19/2025

    LabWare, Inc., the global leader in Laboratory Information Management Systems (LIMS) for more than 30 years, today announces the release of Clinical Health Solution 5.06, the latest version of its purpose-built solution for managing clinical diagnostics and public health laboratory operations.

  7. Plus Therapeutics Announces Successful Accreditation And Certification For Its CNSide® Diagnostics Clinical Laboratory 9/18/2025

    CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it has received a certificate of accreditation from CMS for its lab located in Houston, Texas.

  8. AccuStem Sciences And EmeritusDX Expand Blood-Based Testing Capabilities To Advance Cancer Diagnostics And Treatment Planning 9/17/2025

    AccuStem Sciences, Inc. a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based testing capabilities in partnership with EmeritusDX, a rapidly growing cancer diagnostics and information company.

  9. StatLab Launches PiSmart S1 Slide Printer, And Expands U.S. Manufacturing In Arlington 9/17/2025

    StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the PiSmart S1 single-hopper slide printer, expanding its existing PiSmart labeling and tracking solutions of both slide and cassette printers.

  10. Meridian Bioscience Eliminates Cold Chain With The First Liquid Ambient Temperature Stable qPCR Master Mixes 9/16/2025

    The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of the industry's first liquid qPCR master mixes proven stable for over 12 months at ambient temperatures and shippable with oligos without compromising performance. This breakthrough eliminates the need for refrigeration, freezing, or costly lyophilization (freeze-drying), offering a level of flexibility and convenience not previously available in liquid formats.